MIRXES-B (02629) has announced that on March 3, 2026, the company successfully won the bid for the 2026 Lianxi District Gastric Cancer Screening and Early Intervention Project. This initiative represents the company's first public health cancer early screening program and its inaugural government procurement project in China, marking the official entry of its miRNA liquid biopsy technology into the public health system. This achievement lays a critical foundation for the large-scale implementation of gastric cancer early screening. The project has a budget of 8.1 million yuan, with a maximum bid price of 7.695 million yuan. It will provide gastric cancer early screening services to approximately 30,000 residents in Lianxi District, Jiujiang City, Jiangxi Province, China. With a total population of about 418,000 in Lianxi District, the project will cover approximately 8% of the population, making it the largest public health project for gastric cancer early screening in the region. The project is expected to increase the local early detection rate for gastric cancer and strengthen the regional cancer prevention and control framework. Winning this bid also reflects the company's vision of "intercepting cancer at an early stage." As the company's first public health and government procurement project in China, it will conduct screening services to high-quality standards. Leveraging the advantages of its miRNA liquid biopsy technology, the company will provide residents of Lianxi District with convenient and accurate gastric cancer early screening solutions, contributing to the enhancement of regional public health welfare. The company also plans to use this project as a model to support the broader adoption of gastric cancer early screening technology in similar public health programs and government procurement projects in other regions. The implementation of this project will help Lianxi District establish a closed-loop gastric cancer prevention and control system based on the principle of "screening – diagnosis – intervention – follow-up," which is expected to reduce the region's gastric cancer incidence and mortality rates. This project is also a significant milestone for the company's commercialization efforts, supporting the translation of its research and development capabilities into positive public health applications. It is anticipated that this will further solidify its leading position in the field of cancer early screening and bring accessible early cancer detection services to a broader population.